

# SENTARA HEALTH PLANS

## MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-844-668-1550**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed.**

**For Medicare Members:** Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. Additional indications may be covered at the discretion of the health plan.

**Drug Requested:** Ocrevus® (ocrelizumab) Injection (J2350/C9494) **(Medical)**

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member Sentara #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight: \_\_\_\_\_ Date: \_\_\_\_\_

- ☐ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

### **Recommended Dosage and Administration:**

- **Initial dose:** 300 mg intravenous infusion, followed 2 weeks later by a 2<sup>nd</sup> 300 mg intravenous infusion
- **Subsequent doses:** single 600 mg intravenous infusion every 6 months

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

☐ **Diagnosis - Primary Progressive Multiple Sclerosis (MS)**

(Continued on next page)

- ☐ Prescriber is a Neurologist
- ☐ Member has a confirmed diagnosis of Primary Progressive MS

**☐ Diagnosis - Relapsing-Remitting MS indication**

- ☐ Prescriber is a Neurologist
- ☐ Member has a confirmed diagnosis of relapsing-remitting MS
- ☐ Member has had at least one medically documented clinical relapse within the previous 12 months
- ☐ Member has tried and failed at least **ONE (1)** of the following agents (**verified by chart notes or pharmacy paid claims; check each tried**):

<input type="checkbox"/> Aubagio® (teriflunomide)	<input type="checkbox"/> Avonex® (IFN beta-1b)	<input type="checkbox"/> Bafiertam® (monomethyl fumarate)
<input type="checkbox"/> Betaseron® (IFN beta-1a)	<input type="checkbox"/> Copaxone® (glatiramer acetate)	<input type="checkbox"/> Extavia® (IFN beta-1a)
<input type="checkbox"/> Gilenya® (fingolimod)	<input type="checkbox"/> Kesimpta® (ofatumumab)	<input type="checkbox"/> Lemtrada® (alemtuzumab) (requires medical prior authorization)
<input type="checkbox"/> Mavenclad® (cladribine)	<input type="checkbox"/> Mayzent® (siponimod)	<input type="checkbox"/> Plegridy® (pegylated-IFN beta-1a)
<input type="checkbox"/> Rebif® (IFN beta-1a)	<input type="checkbox"/> Tecfidera® (dimethyl fumarate)	<input type="checkbox"/> Tysabri® (natalizumab) (requires medical prior authorization)
<input type="checkbox"/> Vumerity® (diroximel fumarate)	<input type="checkbox"/> Zeposia® (ozanimod)	

**Medication being provided by (check box below that applies):**

☐ Location/site of drug administration: \_\_\_\_\_

NPI or DEA # of administering location: \_\_\_\_\_

**OR**

☐ Specialty Pharmacy - PropriumRx

For urgent reviews: Practitioner should call Sentara Health Plans Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health Plan's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****